Immunological considerations for COVID-19 vaccine strategies


The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the most formidable challenge to humanity in a century. It is widely believed that prepandemic normalcy will never return until a safe and effective vaccine strategy becomes available and a global vaccination programme is implemented successfully. Here, we discuss the immunological principles that need to be taken into consideration in the development of COVID-19 vaccine strategies. On the basis of these principles, we examine the current COVID-19 vaccine candidates, their strengths and potential shortfalls, and make inferences about their chances of success. Finally, we discuss the scientific and practical challenges that will be faced in the process of developing a successful vaccine and the ways in which COVID-19 vaccine strategies may evolve over the next few years.


The coronavirus disease 2019 (COVID-19) outbreak was first reported in Wuhan, China, in late 2019 and, at the time of writing this article, has since spread to 216 countries and territories1. It has brought the world to a standstill. The respiratory viral pathogen severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected at least 20.1 million individuals and killed more than 737,000 people globally, and counting1. Although physical-distancing and other transmission-mitigation strategies implemented in most countries during the current pandemic have prevented most citizens from being infected, these strategies will paradoxically leave them without immunity to SARS-CoV-2 and thus susceptible to additional waves of infection. Health-care workers, seniors and those with underlying health conditions are at particularly high risk2,3,4. It is widely accepted that the world will not return to its prepandemic normalcy until safe and effective vaccines become available and a global vaccination programme is successfully implemented5.

As COVID-19 is new to humankind and the nature of protective immune responses is poorly understood, it is unclear which vaccine strategies will be most successful. Therefore, it is imperative to develop various vaccine platforms and strategies in parallel. Indeed, since the outbreak began, researchers around the world have been racing to develop COVID-19 vaccines, with at least 166 vaccine candidates currently in preclinical and clinical development5 (Fig. 1). To meet the urgent need for a vaccine, a new pandemic vaccine development paradigm has been proposed that compresses the development timeline from 10–15 years to 1–2 years6. However, there remains a lack of clarity as to what may constitute a safe and immunologically effective COVID-19 vaccine strategy, how to define successful end points in vaccine efficacy testing and what to expect from the global vaccine effort over the next few years. This Review outlines the guiding immunological principles for the design of COVID-19 vaccine strategies and analyses the current COVID-19 vaccine landscape and the challenges ahead.

Fig. 1: The global COVID-19 vaccine landscape.

The six major types of candidate vaccine for coronavirus disease 2019 (COVID-19) are illustrated (live attenuated virus, recombinant viral vectored, inactivated virus, protein subunit, virus-like particles and nucleic acid based), showing the number of candidate vaccines that are currently under clinical and preclinical development. The nucleic acid-based platform includes both mRNA vaccines (6 clinical and 16 preclinical) and plasmid DNA vaccines (4 clinical and 11 preclinical). Data obtained from ref.5.

Natural and vaccine-induced immunity

Although much remains to be understood regarding the immune response to SARS-CoV-2, and vaccine-induced protective immunity may differ from natural immunity owing to the immune-evasion strategies of the virus, improved understanding of the natural immune response will be instrumental in developing effective vaccine and therapeutic strategies. It is particularly relevant to understand the difference in immune responses between asymptomatic, mild and severe cases and at early and late stages of infection, and to understand why seniors are particularly susceptible to COVID-19, whereas the young are better protected. It is estimated that 40–75% of infections may be mild or asymptomatic7,8 and asymptomatic individuals may have a significantly longer duration of viral shedding than their symptomatic counterparts9. Furthermore, that asymptomatic and mildly ill individuals seem to develop low levels of antibody-mediated immunity has important implications for understanding herd immunity.

The initial site of infection of SARS-CoV-2 is the respiratory tract10,11. On entry, SARS-CoV-2 interacts with the angiotensin-converting enzyme 2 (ACE2) receptor on bronchial and alveolar epithelial cells through its spike (S) protein receptor-binding domain (RBD), which is subsequently primed by a specific cellular serine protease, transmembrane protease serine 2 (TMPRSS2), to gain entry12,13. Analysis of transcripts encoding ACE2 and TMPRSS2 by single-cell RNA sequencing has shown that these transcripts are co-expressed in various cell types10,11, and from autopsy studies SARS-CoV-2 can be detected in multiple organs, including the lungs, pharynx, heart, liver, brain and kidneys14.

Innate immune responses

Emerging evidence suggests that the immune response to SARS-CoV-2 is similar in several aspects to the response to SARS-CoV or Middle East respiratory syndrome coronavirus (MERS-CoV), the two coronaviruses responsible for the 2002–2004 SARS outbreak and the 2012 MERS outbreak that originated in China and Saudi Arabia, respectively15,16,17. Like SARS-CoV and MERS-CoV, SARS-CoV-2 suppresses activation of the innate immune system, including dendritic cells18,19, and dampens antiviral type I and type III interferon responses20. This ability of SARS-CoV-2 to subvert the innate immune response may explain the protracted incubation or presymptomatic period of 2–12 days for COVID-19 relative to the 1–4-day incubation period for influenza16. Thus, uncontrolled SARS-CoV-2 replication in the early phase of infection resulting from innate immune suppression probably underpins the ensuing dysregulated inflammatory responses16,21, particularly in severe cases of COVID-19. Such cases are characterized by markedly increased numbers of inflammatory monocytes and neutrophils in blood20,22,23 and CD14+CD16+ monocyte-derived macrophages in the airway20,24, and increased systemic levels of inflammatory cytokines and chemokines20,22,23. A failure to accomplish early control of SARS-CoV-2 infection in the respiratory tract likely results in high viral burden and dysregulated, potentially lethal, inflammatory responses and immunopathology, including acute respiratory distress syndrome. For this reason, seniors and those with co-morbidities may be particularly prone to COVID-19 owing to immunosenescence and their propensity to mount exaggerated inflammatory responses25,26,27. Besides the consideration of vaccine-induced adaptive immunity discussed later, inclusion of the recently emerged concept of trained immunity (Box 1) in COVID-19 vaccine design might further bolster protection, particularly in the early phases of infection.

Antibody responses

IgM and IgG antibodies to SARS-CoV-2 are detectable within 1–2 weeks after the onset of symptoms in most infected individuals28. Although the relationship between neutralizing antibodies and antigen-specific T cells and disease severity and clinical outcomes remains to be understood, high levels of neutralizing antibodies have been observed in convalescent individuals29, which correlate with T cell responses, particularly those of CD4+ T cells30, and seem to offer some benefits in studies of treatment with convalescent plasma31. Recent studies indicate that the magnitude of neutralizing antibody responses is positively correlated with disease severity32. Thus, whereas antibody responses wane within weeks after infection in most people infected with SARS-CoV-2 (ref.32), which is a feature of antibody responses to other ‘common cold’ coronaviruses17, the magnitude of the neutralizing antibody response in asymptomatic individuals is not only smaller but also decreases faster than in symptomatic individuals9.

The major target of neutralizing antibodies to coronaviruses is the S protein, which is composed of S1 and S2 domains. S1 is membrane distal and contains the RBD that binds to the cellular receptor ACE2. S2 is membrane proximal and has a role in membrane fusion33. The S proteins of SARS-CoV and SARS-CoV-2 are 88% identical and both bind to ACE2 with high affinity33. Certain monoclonal and polyclonal antibodies raised to the S protein of SARS-CoV can cross-neutralize SARS-CoV-2 (refs33,34). Antibodies that bind to the S1 RBD block its interaction with ACE2, whereas those that bind to other regions of S1 and S2 can inhibit conformational change of the S protein and block membrane fusion, respectively35,36,37.

During natural immune responses to SARS-CoV-2, high titres of antibodies are also generated against nucleoprotein (N) — the most abundant viral protein38,39,40. Although antibodies to N are unlikely to neutralize the virus, they have been reported to provide protection against mouse hepatitis virus, a coronavirus of mice. Notably, these antibodies were IgG2a, indicating that they may exert protection through Fc-mediated effector functions rather than direct virus neutralization41,42. Somewhat unusually, several studies have reported that IgA responses to S protein peak earlier than IgM responses and are more pronounced, which makes IgA a potentially attractive target for antibody-based diagnostic assays43,44. The mechanistic basis of this early induction of S-specific IgA is not yet clear.

We do not yet understand the durability of the antibody responses to SARS-CoV-2. However, previous longitudinal studies of patients with SARS-CoV infection reported substantial waning of neutralizing antibody titres between 1 year and 2 years after infection45,46. This is consistent with classical studies showing a relatively rapid waning of antibodies to the seasonal coronavirus 229E47. There are currently no immune correlates of protection for SARS-CoV-2 or other human coroanviruses. Thus, it is unclear what titre of neutralizing antibodies is sufficient to confer protection against infection. Establishing such correlates will be essential to guide the development of effective COVID-19 vaccines.

T cell-mediated immunity

Whereas the current successful human antiviral vaccines, such as influenza and measles vaccines, depend largely on the induction of antibody responses, emerging evidence suggests the requirement of both antibody-mediated and T cell-mediated immunity for effective protection against SARS-CoV-2 (refs17,27). It is well known that CD4+ T cell help is important for optimal antibody responses and for CD8+ T cell activation in host defence48. Furthermore, if neutralizing antibody-mediated protection is incomplete, cytotoxic CD8+ T cells are crucial for viral clearance49. One study found that among people who had recovered from COVID-19, 100% had S protein-specific CD4+ T cells in the circulation and 70% had S protein-specific CD8+ T cells in the circulation30, and preclinical studies show a protective role of T cells in host defence against SARS-CoV50.

The 2–12-day incubation or presymptomatic period of SARS-CoV-2 infection is associated not only with virus-mediated innate immune suppression but also with delayed activation of T cells, particularly CD8+ T cells18,19, as is the case for SARS and MERS. People who have recovered from COVID-19 seem to have high levels of both neutralizing antibodies and T cells, and, compared with severe cases, milder cases of COVID-19 have greater numbers of memory CD8+ T cells in the respiratory tract24,29,30. Evidence suggests that the induction of such lung tissue-resident memory T cells (TRM cells) will depend on the route of vaccination. Respiratory mucosal vaccination induces strong lung TRM cell responses, whereas parenteral vaccination fails to do so51,52,53. Experimentally, the airway TRM cells elicited by respiratory mucosal vaccination offered robust protection against SARS-CoV infection54.

The T helper cell (TH cell) phenotype of vaccine-induced T cells is also relevant to the protection they mediate. Less severe cases of SARS were associated with accelerated induction of a TH1 cell response55, whereas TH2 cell responses have been associated with enhancement of lung disease following infection in hosts parenterally vaccinated with inactivated SARS-CoV viral vaccines56,57. Thus, COVID-19 vaccine-induced TRM cells should have a TH1 cell-like phenotype.

These lines of evidence, together with data suggesting that T cell-mediated immunity generally is a more reliable correlate of vaccine protection than antibody titres in seniors26, strongly support the inclusion of T cell responses in COVID-19 vaccine design17,27.

Pre-existing cross-reactive immunity

Emerging evidence indicates that CD4+ T cells in 35% of healthy individuals not exposed to SARS-CoV-2 recognize the SARS-CoV-2 S protein and that CD4+ T cells in 40–60% of unexposed individuals are reactive to SARS-CoV-2 proteins other than S protein30,58. This indicates that there is cross-reactivity between CD4+ T cells specific for SARS-CoV-2 and CD4+ T cells specific for human common cold coronaviruses, SARS-CoV and animal betacoronaviruses17,59,60,61. There are four human coronaviruses — 229E, NL63, OC43 and HKU1 — that account for ~15% of common colds in humans17. Adults may be infected with one of these on average every 2–3 years, such that there could be a degree of pre-existing cross-reactive immunity to SARS-CoV-2 antigens in these people, which offers a potential explanation for differing susceptibility to SARS-CoV-2 infection. In addition to understanding the relationship between such pre-existing immunity to human coronaviruses and host defence against SARS-CoV-2, it will also be important to consider the contribution of COVID-19 vaccine-boosted cross-reactive immune responses to vaccine-induced protective immunity.

Importantly, whereas CD4+ T cells from patients with COVID-19 equally recognize the S1 and S2 subunits of SARS-CoV-2, cross-reactive CD4+ T cells from unexposed individuals recognize the S2 subunit58. CD4+ T cells from patients with COVID-19 cross-react strongly with S2 subunits of the human coronaviruses OC43 and 229E. More than 90% of tested healthy adults also have IgG antibodies specific for all four human common cold coronaviruses17. However, similarly to antibody responses to SARS-CoV and SARS-CoV-2, antibody responses to human coronaviruses wane rapidly within months after infection. Therefore, control of reinfection with human coronaviruses seems mainly to be antibody independent but T cell dependent17.

As coronavirus cross-reactive T cells can be specific for both structural and non-structural viral proteins58,61, the extent of vaccine-boosted cross-reactive T cell responses induced by most protein subunit and recombinant viral-vectored COVID-19 vaccines, which are currently based only on the S protein, will be different from those boosted by multivalent COVID-19 vaccines such as those based on inactivated SARS-CoV-2 virus. One exception could be the use of live attenuated SARS-CoV-2 vaccines as the pre-existing cross-reactive immunity may limit the potency of such vaccines. Finally, it is noteworthy that the significant presence of cross-reactive immunity in some individuals calls for consideration of stratifying clinical trial participants receiving candidate COVID-19 vaccines according to their status of pre-existing coronavirus immunity.

Antibody-dependent enhancement of disease

A potential barrier to the development of safe and efficacious COVID-19 vaccines (Box 2) is the risk that insufficient titres of neutralizing antibodies might trigger antibody-dependent enhancement (ADE) of disease. ADE is most classically associated with dengue virus, whereby cross-reactive but subneutralizing concentrations of antibodies to one virus serotype enhance infection with another serotype in Fcγ receptor (FcγR)-bearing cells, including macrophages62. A common property among viruses that cause ADE is an ability to replicate in macrophages and/or cause them to respond abnormally. Although macrophages do not seem to be a major target of SARS-CoV-2 infection, and the expression of ACE2 on different monocyte and macrophage populations is highly variable, previous data regarding SARS-CoV suggest that FcγRs can facilitate uptake of the virus into macrophages and B cells21,63. Cytokine profiles from patients infected with SARS-CoV-2 resemble those in macrophage activation syndrome and are characterized by high levels of inflammatory cytokines and chemokines21,64,65,66. Furthermore, patients with symptomatic COVID-19 are reported to produce IgG antibodies with reduced fucosylation levels, which in turn promotes their interaction with activating FcγRIIIa67.

The evidence for ADE in the context of SARS-CoV infection is circumstantial. Correlations between antibody titres and infection severity have been reported, but it is unclear whether high antibody titres contribute to disease or whether severe infections elicit higher antibody titres68. Also, macrophages treated in vitro with serum from patients with SARS had exaggerated inflammatory cytokine profiles69,70.

ADE has been reported in some preclinical animal models vaccinated with experimental SARS-CoV vaccines. Ferrets vaccinated with a modified vaccinia virus Ankara (MVA) vaccine expressing full-length S protein had increased infection and hepatitis following challenge71,72. Antibodies to S protein were reported to induce acute lung injury in experimentally infected macaques on the basis of histological examination69. By contrast, hamsters vaccinated with recombinant, full-length SARS-CoV S protein were protected against infection despite the ability of antibodies to mediate entry of SARS-CoV into B cells through FcγRII (ref.73).

Whether ADE occurs in the context of SARS-CoV-2 infection remains unclear but warrants further investigation, focusing directly on whether antibodies increase disease severity and, if so, characterizing the specific properties of these antibodies. What seems clear is that high levels of neutralizing antibodies can mediate protection. Defining the titres of neutralizing antibodies that are protective, ensuring that COVID-19 vaccines can achieve these titres and avoiding waning of antibodies to subneutralizing levels through frequent boosting will be important to minimize the possibility of ADE. Rationally designed COVID-19 vaccines that omit ADE-inducing, non-neutralizing or weakly neutralizing epitopes in favour of those known to mediate protective responses may also minimize the likelihood of disease enhancement. Finally, there is also evidence from mouse models of dengue virus infection that antiviral T cells help to dampen ADE of disease74. Therefore, a vaccine strategy designed to induce both neutralizing antibodies and robust T cell-mediated immunity may help to mitigate the risk of ADE.

Vaccine design

Vaccine design concerns the selection of antigens, vaccine platforms, and vaccination routes and regimen. The choice of vaccine platform determines the relative immunogenic strength of vaccine-derived viral antigens, whether an immune adjuvant is required and the nature of protective immunity. These attributes also determine the suitability of a vaccine for a particular route of vaccination, and whether a prime–boost vaccination regimen is required to increase vaccine-mediated protective immunity and its durability. Furthermore, the selection of live attenuated viral vaccines or a respiratory mucosal route of vaccination will require more stringent safety testing (Box 2).

Selection of SARS-CoV-2 antigens

The structural proteins present in the infectious virion include S protein, N protein, matrix (M) protein and envelope (E) protein. The N protein coats the large positive-stranded RNA genome, which is encased in a lipid envelope derived from the host cell membrane, into which the other three proteins (S, M and E) are inserted. In the case of SARS-CoV, it has been shown that only antibodies directed to S protein can neutralize the virus and prevent infection75. As a result, all SARS-CoV-2 vaccines in development include at least a portion of the S protein. These may be restricted to only the S1 domain or the RBD.

Non-neutralizing antibodies to both S protein and the other exposed proteins (E and M) are generated. As there is a suspected role of these non-neutralizing antibodies, as well as weakly neutralizing antibodies, in ADE of disease, the inclusion of other structural (N) and/or non-structural proteins as vaccine antigens may help to create a more balanced response involving both humoral and T cell-mediated immunity. These could be highly expressed proteins such as N protein or highly conserved functional proteins that have a crucial role in the viral life cycle. For example, inclusion of viral enzymes such as the RNA-dependent RNA polymerase in a vaccine design may ensure that it targets all emerging variant strains, as these proteins are highly conserved59,76,77, even across other bat-derived coronaviruses that could emerge as a threat to humans in the future.

Vaccine platforms

In general, vaccine platforms are divided into six categories: live attenuated virus, recombinant viral-vectored vaccines that are bioengineered to express target pathogen antigens in vivo, inactivated or killed virus, protein subunit vaccines, virus-like particles (VLPs) and nucleic acid-based (DNA or mRNA) vaccines. In broad terms, vaccines require two components: antigens from the target pathogen that are provided to or generated by the vaccine recipient; and an infection signal (such as a pathogen-associated molecular pattern or damage-associated molecular pattern) that alerts and activates the host immune system. Live attenuated vaccines can naturally provide both of these components, whereas non-viral vaccine platforms can provide the antigens but often require the artificial provision of signals to alert the immune system known as adjuvants. Typically, these non-viral vaccine platforms require multiple vaccinations to induce protective immunity, whereas live virus-based vaccines have the ability to provide ‘one-shot’ immunity. Similarly to non-viral platforms, killed virus vaccines sometimes require the inclusion of an adjuvant and repeated administration for full efficacy78. There are immunological pros and cons to each of these technologies as discussed later (Table 1).

Table 1 Immunological properties of major COVID-19 candidate vaccine platforms

Vaccination routes and regimens

In addition to the careful selection of vaccine antigens and platform, the route of vaccination is an integral consideration of vaccine strategies52,79. This is particularly important for mucosal pathogens such as SARS-CoV-2 and those pathogens against which optimal protection requires not only neutralizing antibodies but also innate and adaptive cellular immunity17,80. The best window of opportunity for SARS-CoV-2 control and clearance is the asymptomatic or presymptomatic period of COVID-19 (2–12 days), which is likely to require all of the immune protective elements to be present within the respiratory mucosa before viral entry16,17,27. The route of vaccination has a crucial role in determining this52,81. Protective IgG antibodies induced by parenteral vaccination readily appear at the respiratory mucosa, this being the primary mechanism by which intramuscular injection of measles or influenza vaccine offers protection in humans. However, this route of vaccination is unable to effectively induce mucosal IgA antibodies or TRM cells in the lungs52,81. By comparison, the respiratory mucosal route of vaccination is adept at inducing antibodies and TRM cells in the respiratory mucosa, as well as macrophage-mediated trained immunity52,54,80,81,82,83,84,85 (Box 1). Inactivated virus, protein subunit and nucleic acid vaccines cannot be administered by the respiratory mucosal route owing to their requirement for potentially unsafe immune adjuvants and repeated delivery (Table 1). By contrast, recombinant viral-vectored vaccines, particularly those using human serotype 5 adenovirus (Ad5) or chimpanzee-derived adenovirus (ChAd), are safe and highly effective for respiratory mucosal vaccination79.

Often, weakly immunogenic vaccines based on inactivated virus, protein subunits, nucleic acids or viral vectors such as Ad26 require a repeated homologous vaccination regimen to be effective. Indeed, most current human vaccines require repeated doses. As it is not yet known which COVID-19 vaccine strategy will be used or for how long the vaccine-induced protection may last in humans, it remains possible that a homologous or heterologous prime–boost vaccination regimen will be required to sustain protection, even with robust stand-alone platforms such as ChAd. The same or a different route may be used for the repeated vaccine delivery.

Major COVID-19 vaccine candidates

As of 31 July 2020, there were 27 vaccine candidates for COVID-19 in clinical evaluation and 139 vaccines in preclinical development5 (Fig. 1). Of the 27 vaccines undergoing clinical evaluation (Table 2), the three lead candidates are viral-vectored and mRNA-based vaccines that entered clinical trials in China, the UK and the USA in mid-March 2020. Clinical trials for the remaining 24 candidates are currently recruiting volunteers, and a couple of other candidates are also about to enter clinical trials (Table 2). Preclinical evaluation of candidate vaccines requires the use of relevant animal models of COVID-19 (Box 3). Conventionally, the safety, immunogenicity and protective efficacy of experimental vaccines are rigorously evaluated and established in animal models first before clinical trials are begun. In the case of pandemic vaccine development, however, the preclinical and clinical stages of vaccine development are compressed and move forwards in parallel.

Table 2 COVID-19 vaccine candidates in or entering clinical trials

Live attenuated viral vaccines

Historically, several successful human vaccines, such as measles vaccine and the bacillus Calmette–Guérin (BCG) vaccine for tuberculosis (TB), have been based on attenuated strains of the actual pathogen86, with loss or mutation of virulence genes through in vitro passage. It is now possible to rationally design attenuated virus strains by mutating or deleting virulence genes. These deletion mutants can often replicate to a limited extent in host cells but lose the ability to cause disease in vivo. Coronaviruses have several genes that are not required for replication and that can be deleted, leading to attenuation in vivo. Deletion of various non-structural proteins, as well as of the structural E protein, has been used as a strategy to engineer vaccine strains of several zoonotic and veterinary coronaviruses87,88,89. Deletion of the E protein leads to attenuation and generation of an efficacious vaccine strain87,88, but reversion of the attenuated phenotype has been reported90. Deletion of virulence factors may therefore provide a preferred mechanism of attenuation. For example, deletion of the 2′-O-methylase gene from the SARS-CoV genome removes the ability of the virus to hide its RNA from the host cell proteins MDA5 (also known as IFIH1) and IFIT1, thereby inducing a robust antiviral response in vivo91. Another approach to viral attenuation is known as codon deoptimization, whereby the nucleic acid sequence is modified to use suboptimal codons to encode the wild-type amino acid sequence, which considerably slows the translation of the viral protein during infection. This approach can yield a virus that is highly attenuated in vivo but still able to replicate in vitro if the correct viral protein is selected for deoptimization92,93.

However, the generation of an attenuated strain of a pathogen for use as a vaccine requires demonstration of its inability to revert genetically to become pathogenic (Table 1; Box 2). This is particularly challenging in the case of coronaviruses as they are known to recombine in nature94, and an attenuated vaccine strain could, in theory, recombine with wild coronaviruses to recreate a pathogenic strain. So far, there are only three attenuated SARS-CoV-2 vaccines generated by codon deoptimization under preclinical development, by Mehmet Ali Aydinlar University in Turkey, Codagenix and Serum Institute of India, and Indian Immunologicals Ltd and Griffith University5.

Recombinant viral-vectored vaccines

Recombinant viral-vectored vaccines are built on either a replication-deficient viral backbone or an attenuated replication-competent viral backbone that is bioengineered to express antigens derived from the target pathogen. Although only a couple of viral-vectored vaccines have been approved for human use for the control of infections such as Ebola, this platform has been widely investigated and has a well-established track record for infectious diseases and cancer, given its genetic malleability, safety and ability to induce strong T cell responses without the need for an adjuvant95,96. Some viral vectors, such as Ad5 and ChAd, usually need to be administered only once for protection and have natural tropism for the respiratory mucosa, which means they are amenable to respiratory mucosal vaccination79. The technology already exists for their large-scale clinical grade production and storage.

Thus, recombinant viral vectors are the second most common platform for COVID-19 vaccine development, with 4 candidates currently in clinical trials (Table 2), 38 under preclinical development5 and 3 (ChAdOx1 nCoV-19, Ad26-S and VSV-S) selected for US Operation Warp Speed97 (Table 2). The non-replicating viral platforms are mostly based on Ad5 or MVA, and most of these vaccine candidates express the S protein or RBD of SARS-CoV-2. Replication-competent viral vectors are mainly based on the vaccine strains of other human pathogens (such as measles or influenza viruses) or veterinary pathogens (such as vesicular stomatitis virus (VSV)). However, it will be important to consider whether humans have pre-existing immunity against the viral backbone (Table 1). Pre-existing antibodies can impair the ability of such vaccines to engage the immune system. Use of viral backbones such as ChAd, for which humans have little to no pre-existing immunity, can help to circumvent this issue79.

Ad5-nCOV, which is being developed by the Chinese vaccine company CanSino Biologics, is designed to induce neutralizing antibodies to SARS-CoV-2 S protein following intramuscular injection (Table 2). Without published preclinical data, it entered phase I/II clinical trials with three doses of vaccine tested98,99. Of note, these doses are 10–30 times higher than those used in previous trials of intramuscular vaccines100,101,102. Whereas the highest dose generated unacceptable toxicity and was dropped from the phase II study99, the smaller doses induced S protein-specific neutralizing antibodies in only 50% of the vaccine recipients98. The phase II study largely reaffirms the phase I observations that, although the vaccine induces both antibody and T cell responses, its potency is reduced by pre-existing immunity to Ad5, particularly in elderly participants99. Depending on geographical region, 35–95% of humans have significant circulating levels of neutralizing antibodies to Ad5 (ref.103). This is consistent with the rapidly declining antibody titres observed in a phase II Ad5-Ebola vaccine study104. The vaccine is entering further advanced trials in China and Canada, but the efficacy of this strategy is now in question105. Another human adenovirus-based COVID-19 vaccine, known as Ad26-S, is being developed by Johnson & Johnson, although there is still 40% seroprevalence for Ad26 in humans106. As Ad26 is inherently less immunogenic than Ad5 (ref.107), effective immunity requires repeated homologous or heterologous vaccination, as has been shown in Ad26-HIV and Ad26-Ebola vaccine studies in humans108,109. Nevertheless, a single parenteral administration of an Ad26-vectored COVID-19 vaccine (Ad26.COV2.S) offered robust protection in a non-human primate model of SARS-CoV-2 (ref.110).

ChAdOx1 nCoV-19 (also known as AZD-1222), which is being developed by Oxford University, UK, and AstraZeneca, is the most clinically advanced COVID-19 vaccine (Table 2). Humans have low seroprevalence for ChAd, hence its strong immunogenicity and utility for heterologous prime–boost COVID-19 vaccination79,107,111. The development of ChAdOx1 nCoV-19 is based on promising human studies with ChAdOx1-MERS vaccine112 and ChAdOx1-TB vaccine113. However, although intramuscular delivery of ChAdOx1 nCoV-19 reduced SARS-CoV-2 viral load in the lungs and prevented pneumonia in rhesus macaques, it did not reduce viral loads in the upper respiratory tract114. A recently reported phase I/II study shows its safety and the induction of potent neutralizing antibody and T cell responses following a single parenteral injection, which are boosted further by a second homologous vaccination115. It remains unclear from this trial to what extent both CD4+ and CD8+ T cell subsets were activated.

VSV-S is a replication-competent COVID-19 vaccine under development by Merck116 and other groups. Merck’s vaccine is built upon the licensure of its highly efficacious VSV-Ebola vaccine, which induces neutralizing antibodies and cellular immunity against Ebola virus surface glycoprotein117. VSV is a veterinary virus to which humans have no pre-existing immunity. However, the cloning capacity of the VSV vector is limited to 4 kb, and its suitability for respiratory mucosal vaccination is unclear. A single parenteral vaccination with a VSV vector expressing S protein provides protection against SARS-CoV-2 in both mouse and hamster models118,119. Among other viral-vectored candidates is non-replicating MVA. MVA has widely been explored as a vaccine carrier and has a cloning capacity of up to 30 kb. However, as it is not robustly immunogenic, MVA is often used as a booster vaccine or repeated injection is required to be effective, as was the case in clinical testing of an MVA-MERS-S vaccine120.

Inactivated viral vaccines

Physically or chemically inactivated viruses have been used successfully in human vaccines against polio, hepatitis A and influenza121,122. Inactivated viruses can be rapidly generated and scaled up in a pandemic situation using well-established infrastructure and methods123. Inactivated viral vaccines have few safety concerns, unlike their live attenuated counterparts, and they express a wide range of native viral antigens, including surface antigens with retained epitope conformations that can induce conformation-dependent antibody responses124,125.

Currently, there are five early clinical trials to assess inactivated SARS-CoV-2 vaccines (Table 2), with an additional nine candidates in preclinical development5. PiCoVacc, an inactivated SARS-CoV-2 and alum-adjuvanted vaccine developed by Sinovac Biotech Ltd in China, is the most advanced candidate with published preclinical results126. It protects rhesus macaques against SARS-CoV-2, with reduced viral titres and immunopathology associated with antibodies to S protein and nucleocapsid126. BBIBP-CorV, another inactivated virus candidate, which is being developed by Chinese state-owned Sinopharm, was tested in a range of animal models, with demonstrated efficacy in non-human primates127. Although these findings provide optimism, the observations were made in rather short-term studies and should be interpreted with caution.

Inactivated viral vaccines often require an adjuvant and repeated administration to be effective (Table 1). The use of alum as an adjuvant126,127 makes them unsuitable for respiratory mucosal delivery128. Although the protection mediated by intramuscular immunization with PiCoVacc or BBIBP-CorV indicates some level of mucosal immunity, probably through the transport of systemic antibodies to the lungs, the durability of such immunity remains unclear as SARS-CoV-2 challenge was performed 1–4 weeks after vaccination126,127. Furthermore, similarly to protein subunit vaccines, inactivated viral vaccines are poor inducers of cytotoxic CD8+ T cells, which are likely to be required for an effective COVID-19 vaccine.

Studies with inactivated SARS-CoV and respiratory syncytial virus vaccines have reported vaccine-related enhancement of disease, likely involving a TH2 cell response and lung eosinophilia, which may be worsened in aged hosts56,74,129. Although PiCoVacc or BBIBP-CorV did not worsen lung disease within 7 days after infection, alum is known to drive TH2 cell-mediated immune responses, which warrants further safety investigations. The use of TH1 cell-skewing modified alum or other adjuvants such as CpG may avert such safety concerns130,131.

Protein subunit vaccines

Currently, there are seven COVID-19 subunit vaccines in clinical trials (Table 2), with 50 other candidates under preclinical development, making this the most common platform5. Subunit vaccines primarily induce CD4+ TH cell and antibody responses. Therefore, most of these vaccines contain full-length SARS-CoV-2 S protein or portions of it with the goal of inducing neutralizing antibodies, similarly to the majority of SARS and MERS vaccines, which had differing levels of efficacy132,133,134.

Subunit vaccines can be designed to focus the immune response towards neutralizing epitopes, thereby averting the production of non-neutralizing antibodies that may promote ADE of disease135. However, unlike nucleic acid-based or viral-vectored vaccines, recombinant S proteins in subunit vaccines could have an improper epitope conformation unless they are produced in mammalian cells136. Proteins or peptides alone are poorly immunogenic and generally require not only an adjuvant but also repeated administration, and they are poor activators of CD8+ T cell responses (Table 1). Furthermore, this platform is generally unsuitable for respiratory mucosal vaccination. As is the case for inactivated viral vaccines, use of unmodified alum as an adjuvant skews the immune response towards TH2 cell-like responses56, which is undesirable for host defence against SARS-CoV-2 and may have a role in ADE of disease74,130. In this regard, subunit COVID-19 vaccines being developed by GlaxoSmithKline and Novavax use AS03 and Matrix-M adjuvants, respectively5.

Virus-like particles

VLPs are spontaneously forming particles composed of several structural viral proteins that are co-expressed or admixed. Several commercial vaccines, such as hepatitis B and human papillomavirus vaccines, are based on VLPs137. In the case of enveloped coronaviruses, VLPs form when the viral proteins S, M and E, with or without N, are co-expressed in eukaryotic producer cells138,139. This results in active budding from the producer cells of VLPs that are structurally identical to the infectious virus but lack the viral genome and thus are non-infectious. The presence of S protein on the surface of VLPs enables them to bind and enter ACE2+ cells in the same manner as the parent virus140. Unlike subunit vaccines, the array of S protein on the VLP surface crosslinks the B cell receptor and directly activates B cells, but, like subunit and inactivated viral vaccines, VLPs also typically require an adjuvant and repeated administration137. Notwithstanding this, the VLP technology is well established, the biology and safety of coronavirus VLPs are understood and their large-scale production to Good Manufacturing Practice standards is relatively straightforward.

Currently, there is only 1 VLP-based COVID-19 vaccine in clinical trials (Table 2), with 12 more under preclinical development5. These are produced either in vivo from a viral vector, such as MVA, that expresses the VLP components (a platform being developed by GeoVax) or more often in vitro from producer cells. Notably, Medicago, a Canadian company, produces its SARS-CoV-2 VLPs from genetically engineered plants. Its unpublished results seem to suggest efficacy in inducing neutralizing antibodies in mice141.

Nucleic acid-based vaccines

Recombinant plasmid DNA has been explored as a vaccine platform for decades, whereas mRNA has emerged more recently as a promising platform142,143. Currently, there are 6 mRNA-based COVID-19 vaccines and 4 DNA-based COVID-19 vaccines in clinical trials (Table 2), with 27 such vaccines (16 mRNA-based and 11 DNA-based vaccines) under preclinical development5.

The antigen-encoding mRNA complexed with a carrier such as lipid nanoparticles can be efficiently delivered in vivo into the cytoplasm of host cells for protein translation and post-translational modifications142,144, which is an advantage over recombinant protein subunit vaccines. mRNA vaccines are non-infectious and are synthesized by in vitro transcription, free of microbial molecules. These beneficial features differentiate mRNA vaccines from live attenuated viral vaccines, inactivated viral vaccines, subunit vaccines and recombinant viral-vectored vaccines in terms of safety, efficacy and issues of antivector immunity, enabling their rapid and inexpensive production and repeated vaccination142 (Table 1).

mRNA-1273, which is produced by Moderna, an American biotech company that has experience with mRNA-based MERS vaccines, encodes a prefusion-stabilized SARS-CoV-2 S protein encapsulated in lipid nanoparticles. It entered clinical testing even before the release of preclinical data145. Recently published phase I clinical trial data indicate that low and medium doses of two repeated parenteral injections are generally safe and induce strong S protein-specific antibody responses and a primarily CD4+ T cell response in most trial participants146. Pfizer and BioNTech are also assessing an mRNA–lipid nanoparticle vaccine encoding the S protein RBD (known as BNT162b1) in humans, who developed robust S protein-specific antibody and CD4+ and CD8+ T cell responses following two repeated parenteral injections147,148. The Pfizer/BioNTech and Moderna vaccines have both been selected for US Operation Warp Speed97 (Table 2).

Although no mRNA vaccine has yet been licensed for human use, their potential is supported by previous studies of influenza, rabies and Zika virus infections in animals149,150,151,152,153. For example, an mRNA vaccine for influenza virus induced long-term humoral immunity in young and aged mice149, and an mRNA vaccine for Zika virus induced both antibodies and cytotoxic CD8+ T cells in mice154. However, two clinical studies show disparities in the magnitude and longevity of immune responses induced by mRNA vaccines152,155. Thus, although mRNA-based COVID-19 vaccines show promise from early clinical testing, questions remain about their protective efficacy in humans. It is also unclear whether mRNA vaccines are amenable to respiratory mucosal delivery.

Plasmid DNA vaccines share several characteristics with mRNA vaccines, including safety, ease of production and scalability156. However, they are poorly immunogenic, requiring multiple doses and the addition of an adjuvant. Currently, there are four plasmid DNA-based COVID-19 vaccines in clinical testing (Table 2), with 11 more under preclinical development. INO-4800, a plasmid DNA vaccine expressing SARS-CoV-2 S protein, is being developed by the US biotech company Inovio Pharmaceuticals. A preclinical study in mice and guinea pigs examined the immunogenicity of this vaccine but did not provide any data pertaining to protection against challenge157. Two repeated injections of an S protein-expressing plasmid DNA vaccine resulted in robust protective immunity in rhesus macaques158.

Conclusions and outlook

The world is in dire need of safe, effective COVID-19 vaccine strategies. Many laboratories and companies have scrambled to rapidly develop these vaccines, resulting in more than 160 vaccine candidates, with a handful having entered phase I, II and III clinical trials within a short period of 6 months. Although we are just beginning to understand COVID-19 and its vaccine requirements, most of the advanced vaccine platforms have been extensively explored for other infections and cancer79,95,96,159. While it is important to pursue various vaccine strategies in parallel, it is equally important not to lose sight of this existing scientific knowledge to make well-informed decisions around which strategies to prioritize.

The various vaccine platforms and strategies have their immunological pros and cons (Table 1), but modern immunological principles and data from prior studies of similar platforms lead us to surmise that a parenteral COVID-19 vaccine strategy capable of inducing a robust, durable response involving both neutralizing antibodies and T cells should provide a significant level of protection. Almost all of the current vaccines in the human immunization programme are delivered via the skin or muscle, and most of the current COVID-19 vaccine strategies also focus on the parenteral route of vaccination (Table 2). We further surmise that a respiratory mucosal vaccine strategy capable of inducing these responses directly in the respiratory mucosa will be most effective in the early control or clearance of SARS-CoV-2. This is particularly relevant to high-risk elderly populations, who will require a particularly robust vaccine strategy. In this regard, a respiratory mucosal vaccine strategy for COVID-19 may draw on the successful experience in respiratory mucosal delivery of influenza, measles and TB vaccines to humans160,161,162. Respiratory mucosal vaccination also has the advantages of being needle-free and requiring a much smaller dose than the parenteral route. However, compared with the parenteral route, fewer vaccine platforms are safe and effective for respiratory mucosal vaccination. Furthermore, the use of inhalational devices for respiratory mucosal delivery may potentially be a limiting factor for widespread application in resource-poor settings.

According to the pandemic vaccine development paradigm (Fig. 2), the conventional vaccine development milestones are compressed from a time frame of 10–15 years to 1–2 years, with overlapping preclinical, clinical and scale-up manufacturing processes occurring in parallel6. Owing to the accelerated development process, the interim data from ongoing clinical and preclinical vaccine studies are being published almost in real time. As a result, crucial information about the longevity and quality of vaccine-induced protective immunity is unavailable. As transmission rates and the numbers of new cases have reduced in many countries, it is uncertain whether the phase II and phase III studies of the front-runner candidates will reach a reliable conclusion with regard to their protective efficacy. Furthermore, these vaccine candidates have been studied in isolation, which makes it difficult to directly compare the effectiveness of different candidates. Thus, it would be premature to hail the safety and immunogenicity observed in COVID-19 vaccine trials as a real success. To a large extent, such outcomes could be anticipated from past studies testing the same platforms and delivery routes. Nevertheless, rapid deployment of a vaccine with preclinical efficacy data but limited clinical data to high-risk populations may be necessary (Fig. 2).

Fig. 2: Evolving scenarios for global COVID-19 vaccine development and demand.

In response to the urgent demand for a vaccine, more than two dozen candidate vaccines are advancing through clinical trials following an expedited pandemic vaccine development paradigm, with many steps of the development process occurring in parallel before a successful outcome of previous steps has been confirmed. Vaccine candidates will continue to be preclinically and clinically evaluated following conventional and/or rationalized vaccine development processes over the next few years. These efforts will evolve to meet the demands for vaccination in several likely scenarios that are predicted on the basis of sociopolitical challenges and the emerging data regarding the trajectory of the coronavirus disease 2019 (COVID-19) pandemic and the host response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). One scenario is the priority vaccination of high-risk populations such as health-care workers, seniors, people with co-morbidities and ethnic minorities, who have been disproportionately affected by COVID-19, when vaccine supply is initially limited. Aside from these prioritized groups, it may also be necessary to consider that asymptomatic individuals, patients who have recovered from COVID-19 but generated poor immunity or whose immunity quickly waned, and individuals who received a rapidly developed ‘pandemic’ vaccine that provided suboptimal protection or rapidly waning immune responses may require a booster vaccination to ensure sufficient levels of population protection for herd immunity. Ultimately, regional, continental and global populations will be subject to mass vaccination programmes based on the extent of national and global vaccine distribution and also likely according to the relative regional severity of outbreaks.

The evolving process of vaccine development will continue over the next few years until more clinical trials are completed, additional vaccine strategies are evaluated and host defence against SARS-CoV-2, including postinfection immunity, is better understood (Fig. 2). Probably not until then will global mass immunization become a reality. It is possible that the populations that receive the first round of vaccines will have waning immunity and require boosting using improved second-generation COVID-19 vaccines. Furthermore, in addition to unexposed individuals, some individuals who have recovered from COVID-19 who develop poor or waning immunity may also require vaccination163.

Given the challenges in resources, manufacturing and issues associated with distribution and regional protectionism, the implementation of vaccination programmes will likely be uneven, asynchronous and variable — involving different vaccine platforms and strategies around the globe164,165. In this regard, some resource-rich countries have already secured large numbers of doses of different candidate vaccines without knowing which one may prove effective. The heated debate has begun globally over who should be at the front of the line when vaccine supply is limited. The founding of the COVID-19 Vaccines Global Access (COVAX) Facility by Gavi, the Coalition for Epidemic Preparedness Innovations (CEPI) and the WHO is an attempt to garner resources and unite higher- and lower-income countries for the coordinated, rapid, transparent and equitable access to COVID-19 vaccines worldwide.


  1. 1.

    World Health Organization. WHO coronavirus disease (COVID-19) dashboard. WHO (2020).

  2. 2.

    Chou, R. et al. Epidemiology of and risk factors for coronavirus infection in health care workers. Ann. Intern. Med. (2020).

    Article  PubMed  PubMed Central  Google Scholar 

  3. 3.

    Flaxman, S. et al. Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe. Nature 584, 257–261 (2020).

    CAS  Article  PubMed  Google Scholar 

  4. 4.

    Sanche, S. et al. High contagiousness and rapid spread of severe acute respiratory syndrome coronavirus 2. Emerg. Infect. Dis. 26, 1470–1477 (2020).

    PubMed  PubMed Central  Article  Google Scholar 

  5. 5.

    World Health Organization. Draft landscape of COVID-19 candidate vaccines. WHO (2020).

  6. 6.

    Lurie, N., Saville, M., Hatchett, R. & Halton, J. Developing Covid-19 vaccines at pandemic speed. N. Engl. J. Med. 382, 1969–1973 (2020). This article describes the differences between the pandemic vaccine development and the conventional rationalized vaccine development paradigms and timelines.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  7. 7.

    Chau, N. V. V. et al. The natural history and transmission potential of asymptomatic SARS-CoV-2 infection. Clin. Infect. Dis. (2020).

  8. 8.

    Poletti, P. et al. Probability of symptoms and critical disease after SARS-CoV-2 infection. Preprint at arXiv (2020). Chau et al. (2020) and Poletti et al. indicate high rates of asymptomatic individuals following SARS-CoV-2 exposure.

  9. 9.

    Long, Q.-X. et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat. Med. 26, 1200–1204 (2020). This study provides evidence that asymptomatic individuals infected with SARS-CoV-2 can shed the virus for a significantly longer time than their symptomatic counterparts and that immune responses, including antibody responses, in asymptomatic individuals are not only lower but also decrease faster during the convalescent phase.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  10. 10.

    Sungnak, W. et al. SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. Nat. Med. 26, 681–687 (2020).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  11. 11.

    Zou, X. et al. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. Front. Med. 14, 185–192 (2020).

    PubMed  Article  PubMed Central  Google Scholar 

  12. 12.

    Hoffmann, M. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181, 271–280.e8 (2020). This is one of the first studies to identify ACE2 and TMPRSS2 as the cell surface receptor molecules used by SARS-CoV-2 for infection.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  13. 13.

    Sallenave, J.-M. & Guillot, L. Innate immune signaling and proteolytic pathways in the resolution or exacerbation of SARS-CoV-2 in Covid-19: key therapeutic targets? Front. Immunol. 11, 1229 (2020).

    PubMed  PubMed Central  Article  Google Scholar 

  14. 14.

    Puelles, V. G. et al. Multiorgan and renal tropism of SARS-CoV-2. N. Engl. J. Med. 383, 590–592 (2020).

    PubMed  Article  PubMed Central  Google Scholar 

  15. 15.

    de Wit, E., van Doremalen, N., Falzarano, D. & Munster, V. J. SARS and MERS: recent insights into emerging coronaviruses. Nat. Rev. Microbiol. 14, 523–534 (2016).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  16. 16.

    Prompetchara, E., Ketloy, C. & Palaga, T. Immune responses in COVID-19 and potential vaccines: lessons learned from SARS and MERS epidemic. Asian Pac. J. Allergy Immunol. 38, 1–9 (2020).

    Google Scholar 

  17. 17.

    Sariol, A. & Perlman, S. Lessons for COVID-19 immunity from other coronavirus infections. Immunity (2020).

  18. 18.

    Zhou, R. et al. Acute SARS-CoV-2 infection impairs dendritic cell and T cell responses. Immunity 53, 1–14 (2020). This study documents SARS-CoV-2-mediated innate immune suppression associated with impaired dendritic cell responses and, subsequently, delayed T cell activation in infected individuals.

    Article  CAS  Google Scholar 

  19. 19.

    Remy, K. E. et al. Severe immunosuppression and not a cytokine storm characterize COVID-19 infections. JCI Insight (2020).

    Article  Google Scholar 

  20. 20.

    Blanco-Melo, D. et al. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell 181, 1036–1045.e9 (2020).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  21. 21.

    Merad, M. & Martin, J. C. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. Nat. Rev. Immunol. 20, 355–362 (2020).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  22. 22.

    Zhou, Y. et al. Pathogenic T-cells and inflammatory monocytes incite inflammatory storms in severe COVID-19 patients. Natl Sci. Rev. 7, 998–1002 (2020).

    CAS  Article  Google Scholar 

  23. 23.

    Zhou, F. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395, 1054–1062 (2020).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  24. 24.

    Liao, M. et al. Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19. Nat. Med. 26, 842–844 (2020).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  25. 25.

    Fulop, T. et al. Immunosenescence and inflamm-aging as two sides of the same coin: friends or foes? Front. Immunol. 8, 1960 (2017).

    PubMed  Article  CAS  PubMed Central  Google Scholar 

  26. 26.

    Haq, K. & McElhaney, J. E. Immunosenescence: influenza vaccination and the elderly. Curr. Opin. Immunol. 29, 38–42 (2014). Fulop et al. (2017) and Haq and McElhaney discuss a unique challenge for developing effective and safe vaccine strategies for seniors, who are among those most in need of vaccine-mediate immune protection from COVID-19, and suggest that vaccine-induced T cell immunity is more important than antibody responses in seniors.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  27. 27.

    Tay, M. Z., Poh, C. M., Rénia, L., MacAry, P. A. & Ng, L. F. P. The trinity of COVID-19: immunity, inflammation and intervention. Nat. Rev. Immunol. 20, 363–374 (2020).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  28. 28.

    Zhao, J. et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clin. Infect. Dis. (2020).

    Article  PubMed  PubMed Central  Google Scholar 

  29. 29.

    Ni, L. et al. Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals. Immunity 52, 971–977.e3 (2020).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  30. 30.

    Grifoni, A. et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell 181, 1489–1501.e15 (2020).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  31. 31.

    Shen, C. et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA 323, 1582 (2020).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  32. 32.

    Seow, J. et al. Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection. Preprint at medRxiv (2020). This study follows the kinetic changes in neutralizing antibody levels up to 94 days after the onset of COVID-19 symptoms; it finds that antibody levels are positively correlated with the severity of disease and decline rapidly, bringing into question the value of serological assessment and the role of such neutralizing antibodies in herd immunity.

    Article  Google Scholar 

  33. 33.

    Walls, A. C. et al. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 181, 281–292.e6 (2020).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  34. 34.

    Pinto, D. et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature 583, 290–295 (2020).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  35. 35.

    Jiang, S., Hillyer, C. & Du, L. Neutralizing antibodies against SARS-CoV-2 and other human coronaviruses. Trends Immunol. 41, 355–359 (2020).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  36. 36.

    Duan, J. et al. A human SARS-CoV neutralizing antibody against epitope on S2 protein. Biochem. Biophys. Res. Commun. 333, 186–193 (2005).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  37. 37.

    Coughlin, M. et al. Generation and characterization of human monoclonal neutralizing antibodies with distinct binding and sequence features against SARS coronavirus using XenoMouse®. Virology 361, 93–102 (2007).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  38. 38.

    To, K. K. W. et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect. Dis. 20, 565–574 (2020).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  39. 39.

    Liu, W. et al. Evaluation of nucleocapsid and spike protein-based enzyme-linked immunosorbent assays for detecting antibodies against SARS-CoV-2. J. Clin. Microbiol. 58, e00461-20 (2020).

    PubMed  PubMed Central  Article  Google Scholar 

  40. 40.

    Long, Q. X. et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat. Med. 26, 845–848 (2020).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  41. 41.

    Nakanaga, K., Yamanouchi, K. & Fujiwara, K. Protective effect of monoclonal antibodies on lethal mouse hepatitis virus infection in mice. J. Virol. 59, 168–171 (1986).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  42. 42.

    Lecomte, J. et al. Protection from mouse hepatitis virus type 3-induced acute disease by an anti-nucleoprotein monoclonal antibody. Arch. Virol. 97, 123–130 (1987).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  43. 43.

    Yu, H. et al. Distinct features of SARS-CoV-2-specific IgA response in COVID-19 patients. Eur. Respir. J. (2020).

    Article  PubMed  PubMed Central  Google Scholar 

  44. 44.

    Padoan, A. et al. IgA-Ab response to spike glycoprotein of SARS-CoV-2 in patients with COVID-19: a longitudinal study. Clin. Chim. Acta 507, 164–166 (2020).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  45. 45.

    Cao, W.-C., Liu, W., Zhang, P.-H., Zhang, F. & Richardus, J. H. Disappearance of antibodies to SARS-associated coronavirus after recovery. N. Engl. J. Med. 357, 1162–1163 (2007).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  46. 46.

    Wu, L. P. et al. Duration of antibody responses after severe acute respiratory syndrome. Emerg. Infect. Dis. 13, 1562–1564 (2007).

    PubMed  PubMed Central  Article  Google Scholar 

  47. 47.

    Callow, K. A., Parry, H. F., Sergeant, M. & Tyrrell, D. A. J. The time course of the immune response to experimental coronavirus infection of man. Epidemiol. Infect. 105, 435–446 (1990).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  48. 48.

    Chen, K. & Kolls, J. K. T cell–mediated host immune defenses in the lung. Annu. Rev. Immunol. 31, 605–633 (2013).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  49. 49.

    Arunachalam, P. S. et al. T cell-inducing vaccine durably prevents mucosal SHIV infection even with lower neutralizing antibody titers. Nat. Med. 26, 932–940 (2020). This non-human primate study compares a vaccine strategy focused on inducing neutralizing antibodies with a vaccine that induces both neutralizing antibodies and T cell-mediated immunity, including vaginal TRM cells, and describes the importance of protective T cells, particularly when neutralizing antibody levels are suboptimal. This study lends further support to including robust T cell responses in the design of COVID-19 vaccine strategies.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  50. 50.

    Zhao, J., Zhao, J. & Perlman, S. T cell responses are required for protection from clinical disease and for virus clearance in severe acute respiratory syndrome coronavirus-infected mice. J. Virol. 84, 9318–9325 (2010).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  51. 51.

    Turner, D. L. et al. Lung niches for the generation and maintenance of tissue-resident memory T cells. Mucosal Immunol. 7, 501–510 (2014).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  52. 52.

    Jeyanathan, M., Yao, Y., Afkhami, S., Smaill, F. & Xing, Z. New tuberculosis vaccine strategies: taking aim at un-natural immunity. Trends Immunol. 39, 419–433 (2018). This recent review highlights the major immunological differences and protective outcomes between parenteral and respiratory mucosal routes of vaccination and suggests ways in which to induce holistic mucosal immunity to mucosal pathogens.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  53. 53.

    Haddadi, S. et al. Mucosal-pull induction of lung-resident memory CD8 T cells in parenteral TB vaccine-primed hosts requires cognate antigens and CD4 T Cells. Front. Immunol. 10, 2075 (2019).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  54. 54.

    Zhao, J. et al. Airway memory CD4+ T cells mediate protective immunity against emerging respiratory coronaviruses. Immunity 44, 1379–1391 (2016).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  55. 55.

    Janice Oh, H.-L., Ken-En Gan, S., Bertoletti, A. & Tan, Y.-J. Understanding the T cell immune response in SARS coronavirus infection. Emerg. Microbes Infect. 1, 1–6 (2012).

    Article  CAS  Google Scholar 

  56. 56.

    Bolles, M. et al. A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge. J. Virol. 85, 12201–12215 (2011).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  57. 57.

    Tseng, C.-T. et al. Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus. PLoS ONE 7, e35421 (2012).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  58. 58.

    Braun, J. et al. SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19. Nature (2020).

    Article  PubMed  PubMed Central  Google Scholar 

  59. 59.

    Ahmed, S. F., Quadeer, A. A. & McKay, M. R. Preliminary identification of potential vaccine targets for the COVID-19 coronavirus (SARS-CoV-2) based on SARS-CoV immunological studies. Viruses 12, 254 (2020).

    CAS  Article  Google Scholar 

  60. 60.

    Mateus, J. et al. Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans. Science (2020).

    Article  PubMed  PubMed Central  Google Scholar 

  61. 61.

    Le Bert, N. et al. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature (2020). Braun et al. (2020), Mateus et al. (2020) and Le Bert et al. consistently find the presence, in a significant proportion of uninfected individuals, of memory CD4+ T cells cross-reactive to SARS-CoV-2, likely resulting from previous exposure to common cold coronaviruses as well as animal coronaviruses. These findings offer a potential mechanism underlying differential susceptibility to SARS-CoV-2 infection and suggest that a COVID-19 vaccine may boost such pre-existing cross-reactive memory T cells in some individuals.

  62. 62.

    Screaton, G., Mongkolsapaya, J., Yacoub, S. & Roberts, C. New insights into the immunopathology and control of dengue virus infection. Nat. Rev. Immunol. 15, 745–759 (2015).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  63. 63.

    Aguiar, J. A. et al. Gene expression and in situ protein profiling of candidate SARS-CoV-2 receptors in human airway epithelial cells and lung tissue. Eur. Respir. J. (2020).

    Article  PubMed  PubMed Central  Google Scholar 

  64. 64.

    Mehta, P. et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 395, 1033–1034 (2020).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  65. 65.

    Schulert, G. S. & Grom, A. A. Pathogenesis of macrophage activation syndrome and potential for cytokine-directed therapies. Annu. Rev. Med. 66, 145–159 (2015).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  66. 66.

    Huang, C. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395, 497–506 (2020).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  67. 67.

    Chakraborty, S. et al. Symptomatic SARS-CoV-2 infections display specific IgG Fc structures. Preprint at medRxiv (2020).

    Article  PubMed  PubMed Central  Google Scholar 

  68. 68.

    Lee, N. et al. Anti-SARS-CoV IgG response in relation to disease severity of severe acute respiratory syndrome. J. Clin. Virol. 35, 179–184 (2006).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  69. 69.

    Liu, L. et al. Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection. JCI Insight 4, e123158 (2019).

    Article  Google Scholar 

  70. 70.

    Eroshenko, N. et al. Implications of antibody-dependent enhancement of infection for SARS-CoV-2 countermeasures. Nat. Biotechnol. 38, 789–791 (2020).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  71. 71.

    Weingartl, H. et al. Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets. J. Virol. 78, 12672–12676 (2004).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  72. 72.

    Czub, M., Weingartl, H., Czub, S., He, R. & Cao, J. Evaluation of modified vaccinia virus Ankara based recombinant SARS vaccine in ferrets. Vaccine 23, 2273–2279 (2005).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  73. 73.

    Kam, Y. W. et al. Antibodies against trimeric S glycoprotein protect hamsters against SARS-CoV challenge despite their capacity to mediate FcγRII-dependent entry into B cells in vitro. Vaccine 25, 729–740 (2007).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  74. 74.

    Diamond, M. S. & Pierson, T. C. The challenges of vaccine development against a new virus during a pandemic. Cell Host Microbe 27, 699–703 (2020).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  75. 75.

    Buchholz, U. J. et al. Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity. Proc. Natl Acad. Sci. 101, 9804–9809 (2004).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  76. 76.

    Stephensen, C. B., Casebolt, D. B. & Gangopadhyay, N. N. Phylogenetic analysis of a highly conserved region of the polymerase gene from 11 coronaviruses and development of a consensus polymerase chain reaction assay. Virus Res. 60, 181–189 (1999).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  77. 77.

    Gao, Y. et al. Structure of the RNA-dependent RNA polymerase from COVID-19 virus. Science 368, 779–782 (2020).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  78. 78.

    Rauch, S., Jasny, E., Schmidt, K. E. & Petsch, B. New vaccine technologies to combat outbreak situations. Front. Immunol. 9, 1963 (2018).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  79. 79.

    Afkhami, S., Yao, Y. & Xing, Z. Methods and clinical development of adenovirus-vectored vaccines against mucosal pathogens. Mol. Ther. Methods Clin. Dev. 3, 16030 (2016).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  80. 80.

    Moreno-Fierros, L., García-Silva, I. & Rosales-Mendoza, S. Development of SARS-CoV-2 vaccines: should we focus on mucosal immunity? Expert. Opin. Biol. Ther. 20, 831–836 (2020).

    Article  Google Scholar 

  81. 81.

    Belyakov, I. M. & Ahlers, J. D. What role does the route of immunization play in the generation of protective immunity against mucosal pathogens? J. Immunol. 183, 6883–6892 (2009).

    CAS  Article  Google Scholar 

  82. 82.

    Szabo, P. A., Miron, M. & Farber, D. L. Location, location, location: tissue resident memory T cells in mice and humans. Sci. Immunol. 4, eaas9673 (2019).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  83. 83.

    Xing, Z. et al. Innate immune memory of tissue-resident macrophages and trained innate immunity: re-vamping vaccine concept and strategies. J. Leukoc. Biol. (2020).

    Article  Google Scholar 

  84. 84.

    Netea, M. G. et al. Trained immunity: a tool for reducing susceptibility to and the severity of SARS-CoV-2 infection. Cell 181, 969–977 (2020).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  85. 85.

    Yao, Y. et al. Induction of autonomous memory alveolar macrophages requires T cell help and is critical to trained immunity. Cell 175, 1634–1650.e17 (2018). Xing et al. (2020), Netea et al. (2020) and Yao et al. describe the emerging concept of trained innate immunity and suggest strategies to harness this concept for developing vaccines against respiratory mucosal pathogens such as SARS-CoV-2.

    CAS  Article  Google Scholar 

  86. 86.

    Plotkin, S. History of vaccination. Proc. Natl Acad. Sci. USA 111, 12283–12287 (2014).

    CAS  Article  Google Scholar 

  87. 87.

    Almazán, F. et al. Engineering a replication-competent, propagation-defective middle east respiratory syndrome coronavirus as a vaccine candidate. MBio 4, e00650-13 (2013).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  88. 88.

    Netland, J. et al. Immunization with an attenuated severe acute respiratory syndrome coronavirus deleted in E protein protects against lethal respiratory disease. Virology 399, 120–128 (2010).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  89. 89.

    Hou, Y., Meulia, T., Gao, X., Saif, L. J. & Wang, Q. Deletion of both the tyrosine-based endocytosis signal and the endoplasmic reticulum retrieval signal in the cytoplasmic tail of spike protein attenuates porcine epidemic diarrhea virus in pigs. J. Virol. 93, e01758-18 (2018).

    Article  Google Scholar 

  90. 90.

    Jimenez-Guardeño, J. M. et al. Identification of the mechanisms causing reversion to virulence in an attenuated SARS-CoV for the design of a genetically stable vaccine. PLoS Pathog. 11, e1005215 (2015).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  91. 91.

    Menachery, V. D. et al. Attenuation and restoration of severe acute respiratory syndrome coronavirus mutant lacking 2’-O-methyltransferase activity. J. Virol. 88, 4251–4264 (2014).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  92. 92.

    Cheng, B. Y. H., Ortiz-Riaño, E., Nogales, A., de la Torre, J. C. & Martínez-Sobrido, L. Development of live-attenuated arenavirus vaccines based on codon deoptimization. J. Virol. 89, 3523–3533 (2015).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  93. 93.

    Mueller, S. et al. A codon-pair deoptimized live-attenuated vaccine against respiratory syncytial virus is immunogenic and efficacious in non-human primates. Vaccine 38, 2943–2948 (2020).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  94. 94.

    Tao, Y. et al. Surveillance of bat coronaviruses in Kenya identifies relatives of human coronaviruses NL63 and 229E and their recombination history. J. Virol. 91, e01953-16 (2017).

    PubMed  PubMed Central  Article  Google Scholar 

  95. 95.

    Humphreys, I. R. & Sebastian, S. Novel viral vectors in infectious diseases. Immunology 153, 1–9 (2018).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  96. 96.

    Draper, S. J. & Heeney, J. L. Viruses as vaccine vectors for infectious diseases and cancer. Nat. Rev. Microbiol. 8, 62–73 (2010).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  97. 97.

    Cohen, J. Top U.S. scientists left out of White House selection of COVID-19 vaccine short list. Science (2020).

    Article  PubMed  PubMed Central  Google Scholar 

  98. 98.

    Zhu, F.-C. et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet 395, 1845–1854 (2020).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  99. 99.

    Zhu, F.-C. et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet (2020). The phase I and phase II human studies by Zhu et al. evaluate an Ad5-vectored COVID-19 vaccine expressing the S protein, representing the first COVID-19 vaccine globally that entered clinical trials and published results. Pre-existing vector immunity occurred in a significant portion of trial participants.

    Article  PubMed  PubMed Central  Google Scholar 

  100. 100.

    Smaill, F. et al. A human type 5 adenovirus-based tuberculosis vaccine induces robust T cell responses in humans despite preexisting anti-adenovirus immunity. Sci. Transl Med. 5, 205ra134 (2013).

    PubMed  Article  CAS  PubMed Central  Google Scholar 

  101. 101.

    Ledgerwood, J. E. et al. A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults. Vaccine 29, 304–313 (2010).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  102. 102.

    Gray, G. E. et al. Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study. Lancet. Infect. Dis. 11, 507–515 (2011).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  103. 103.

    Xiang, Z. et al. Chimpanzee adenovirus antibodies in humans, sub-Saharan Africa. Emerg. Infect. Dis. 12, 1596–1599 (2006).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  104. 104.

    Zhu, F.-C. et al. Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 389, 621–628 (2017).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  105. 105.

    Cross, R. CanSino publishes first COVID-19 vaccine data to muted response. Chemical & Engineering News (2020).

  106. 106.

    Zhang, S. et al. Seroprevalence of neutralizing antibodies to human adenoviruses type-5 and type-26 and chimpanzee adenovirus type-68 in healthy Chinese adults. J. Med. Virol. 85, 1077–1084 (2013). Xiang et al. (2006) and Zhang et al. compare the prevalence of pre-existing circulating neutralizing antibodies (antivector immunity) to Ad5, Ad26 and ChAd platforms in various parts of the world. The relative prevalence of pre-existing antivector immunity is of importance for the choice of viral platforms.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  107. 107.

    Colloca, S. et al. Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species. Sci. Transl Med. 4, 115ra2 (2012).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  108. 108.

    Baden, L. R. et al. First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001). J. Infect. Dis. 207, 240–247 (2013).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  109. 109.

    Anywaine, Z. et al. Safety and immunogenicity of a 2-dose heterologous vaccination regimen with Ad26.ZEBOV and MVA-BN-Filo Ebola vaccines: 12-month data from a phase 1 randomized clinical trial in Uganda and Tanzania. J. Infect. Dis. 220, 46–56 (2019).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  110. 110.

    Mercado, N. B. et al. Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. Nature (2020).

    Article  PubMed  PubMed Central  Google Scholar 

  111. 111.

    Ewer, K. et al. Chimpanzee adenoviral vectors as vaccines for outbreak pathogens. Hum. Vaccin. Immunother. 13, 3020–3032 (2017).

    PubMed  PubMed Central  Article  Google Scholar 

  112. 112.

    Folegatti, P. M. et al. Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial. Lancet. Infect. Dis. 20, 816–826 (2020).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  113. 113.

    Wilkie, M. et al. A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime – MVA85A boost in healthy UK adults. Vaccine 38, 779–789 (2020).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  114. 114.

    van Doremalen, N. et al. ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques. Nature (2020).

    Article  PubMed  PubMed Central  Google Scholar 

  115. 115.

    Folegatti, P. M. et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet (2020). This clinical phase I/II study evaluates a ChAd-vectored COVID-19 vaccine expressing the S protein, showing induction of strong neutralizing antibody and overall T cell responses and representing the third published human COVID-19 vaccine trial in the world. This vaccine is the most advanced COVID-19 vaccine candidate in terms of clinical development.

    Article  PubMed  PubMed Central  Google Scholar 

  116. 116.

    Henao-Restrepo, A. M. et al. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. Lancet 386, 857–866 (2015).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  117. 117.

    Cohen, J. Merck, one of Big Pharma’s biggest players, reveals its COVID-19 vaccine and therapy plans. Science (2020).

  118. 118.

    Case, J. B. et al. Replication-competent vesicular stomatitis virus vaccine vector protects against SARS-CoV-2-mediated pathogenesis in mice. Cell Host Microbe (2020).

    Article  PubMed  PubMed Central  Google Scholar 

  119. 119.

    Yahalom-Ronen, Y. et al. A single dose of recombinant VSV-ΔG-spike vaccine provides protection against SARS-CoV-2 challenge. Preprint at bioRxiv (2020).

    Article  Google Scholar 

  120. 120.

    Koch, T. et al. Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial. Lancet Infect. Dis. 20, 827–838 (2020).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  121. 121.

    Murdin, A. D., Barreto, L. & Plotkin, S. Inactivated poliovirus vaccine: past and present experience. Vaccine 14, 735–746 (1996).

    CAS  Article  Google Scholar 

  122. 122.

    Vellozzi, C. et al. Safety of trivalent inactivated influenza vaccines in adults: background for pandemic influenza vaccine safety monitoring. Vaccine 27, 2114–2120 (2009).

    CAS  Article  Google Scholar 

  123. 123.

    Wood, J. M. & Robertson, J. S. From lethal virus to life-saving vaccine: developing inactivated vaccines for pandemic influenza. Nat. Rev. Microbiol. 2, 842–847 (2004).

    CAS  Article  Google Scholar 

  124. 124.

    Tahir Ul Qamar, M. et al. Epitope-based peptide vaccine design and target site depiction against Middle East respiratory syndrome coronavirus: an immune-informatics study. J. Transl Med. 17, 362 (2019).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  125. 125.

    Watanabe, Y., Allen, J. D., Wrapp, D., McLellan, J. S. & Crispin, M. Site-specific glycan analysis of the SARS-CoV-2 spike. Science 369, 330–333 (2020).

    CAS  PubMed  PubMed Central  Google Scholar 

  126. 126.

    Wang, H. et al. Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2. Cell 182, 713–721.e9 (2020).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  127. 127.

    Gao, Q. et al. Development of an inactivated vaccine candidate for SARS-CoV-2. Science 369, 77–81 (2020).

    CAS  Article  Google Scholar 

  128. 128.

    Zeng, L. Mucosal adjuvants: opportunities and challenges. Hum. Vaccin. Immunother. 12, 2456–2458 (2016).

    PubMed  PubMed Central  Article  Google Scholar 

  129. 129.

    Iwata-Yoshikawa, N. et al. Effects of toll-like receptor stimulation on eosinophilic infiltration in lungs of BALB/c mice immunized with UV-inactivated severe acute respiratory syndrome-related coronavirus vaccine. J. Virol. 88, 8597–8614 (2014).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  130. 130.

    Del Giudice, G., Rappuoli, R. & Didierlaurent, A. M. Correlates of adjuvanticity: a review on adjuvants in licensed vaccines. Semin. Immunol. 39, 14–21 (2018).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  131. 131.

    HogenEsch, H., O’Hagan, D. T. & Fox, C. B. Optimizing the utilization of aluminum adjuvants in vaccines: you might just get what you want. NPJ Vaccines 3, 51 (2018).

    PubMed  PubMed Central  Article  Google Scholar 

  132. 132.

    Mou, H. et al. The receptor binding domain of the new Middle East respiratory syndrome coronavirus maps to a 231-residue region in the spike protein that efficiently elicits neutralizing antibodies. J. Virol. 87, 9379–9383 (2013).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  133. 133.

    Guo, Y. et al. Elicitation of immunity in mice after immunization with the S2 subunit of the severe acute respiratory syndrome coronavirus. DNA Cell Biol. 24, 510–515 (2005).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  134. 134.

    Zhou, Y., Jiang, S. & Du, L. Prospects for a MERS-CoV spike vaccine. Expert. Rev. Vaccines 17, 677–686 (2018).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  135. 135.

    Oscherwitz, J. The promise and challenge of epitope-focused vaccines. Hum. Vaccin. Immunother. 12, 2113–2116 (2016).

    PubMed  PubMed Central  Article  Google Scholar 

  136. 136.

    Du, L. et al. Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and E. coli cells elicits potent neutralizing antibody and protective immunity. Virology 393, 144–150 (2009).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  137. 137.

    Donaldson, B., Lateef, Z., Walker, G. F., Young, S. L. & Ward, V. K. Virus-like particle vaccines: immunology and formulation for clinical translation. Expert. Rev. Vaccines 17, 833–849 (2018).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  138. 138.

    Lu, X. et al. Immune responses against severe acute respiratory syndrome coronavirus induced by virus-like particles in mice. Immunology 122, 496–502 (2007).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  139. 139.

    Lokugamage, K. G. et al. Chimeric coronavirus-like particles carrying severe acute respiratory syndrome coronavirus (SCoV) S protein protect mice against challenge with SCoV. Vaccine 26, 797–808 (2008).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  140. 140.

    Naskalska, A. et al. Novel coronavirus-like particles targeting cells lining the respiratory tract. PLoS ONE 13, e0203489 (2018).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  141. 141.

    Business Wire. Medicago announces positive results in animal trials for its vaccine candidate against COVID-19. STT (2020).

  142. 142.

    Pardi, N., Hogan, M. J., Porter, F. W. & Weissman, D. mRNA vaccines - a new era in vaccinology. Nat. Rev. Drug. Discov. 17, 261–279 (2018).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  143. 143.

    Jackson, N. A. C., Kester, K. E., Casimiro, D., Gurunathan, S. & DeRosa, F. The promise of mRNA vaccines: a biotech and industrial perspective. NPJ Vaccines 5, 11 (2020).

    PubMed  PubMed Central  Article  Google Scholar 

  144. 144.

    Lutz, J. et al. Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines. NPJ Vaccines 2, 29 (2017).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  145. 145.

    Corbett, K. S. et al. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature (2020).

    Article  PubMed  PubMed Central  Google Scholar 

  146. 146.

    Jackson, L. A. et al. An mRNA vaccine against SARS-CoV-2 - preliminary report. N. Engl. J. Med. (2020). This clinical phase I study evaluates an mRNA-based COVID-19 vaccine expressing the S protein, showing induction of strong neutralizing antibody and CD4+ T cell responses in most participants and representing the second published human COVID-19 vaccine trial in the world.

    Article  PubMed  PubMed Central  Google Scholar 

  147. 147.

    Mulligan, M. J. et al. Phase 1/2 study of COVID-19 RNA vaccine BNT162b1 in adults. Nature (2020).

    Article  PubMed  PubMed Central  Google Scholar 

  148. 148.

    Sahin, U. et al. Concurrent human antibody and TH1 type T-cell responses elicited by a COVID-19 RNA vaccine. Preprint at medRxiv (2020).

    Article  PubMed  PubMed Central  Google Scholar 

  149. 149.

    Petsch, B. et al. Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection. Nat. Biotechnol. 30, 1210–1216 (2012).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  150. 150.

    Chahal, J. S. et al. Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and Toxoplasma gondii challenges with a single dose. Proc. Natl Acad. Sci. USA 113, E4133–E4142 (2016).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  151. 151.

    Schnee, M. et al. An mRNA vaccine encoding rabies virus glycoprotein induces protection against lethal infection in mice and correlates of protection in adult and newborn pigs. PLoS Negl. Trop. Dis. 10, e0004746 (2016).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  152. 152.

    Bahl, K. et al. Preclinical and clinical demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9 influenza viruses. Mol. Ther. 25, 1316–1327 (2017).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  153. 153.

    Pardi, N. et al. Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination. Nature 543, 248–251 (2017).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  154. 154.

    Chahal, J. S. et al. An RNA nanoparticle vaccine against Zika virus elicits antibody and CD8 + T cell responses in a mouse model. Sci. Rep. 7, 252 (2017).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  155. 155.

    Alberer, M. et al. Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial. Lancet 390, 1511–1520 (2017).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  156. 156.

    Hobernik, D. & Bros, M. DNA vaccines—how far from clinical use? Int. J. Mol. Sci. 19, 3605 (2018).

    Article  CAS  Google Scholar 

  157. 157.

    Smith, T. R. F. et al. Immunogenicity of a DNA vaccine candidate for COVID-19. Nat. Commun. 11, 2601 (2020).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  158. 158.

    Yu, J. et al. DNA vaccine protection against SARS-CoV-2 in rhesus macaques. Science (2020).

    Article  PubMed  PubMed Central  Google Scholar 

  159. 159.

    Lichty, B. D., Breitbach, C. J., Stojdl, D. F. & Bell, J. C. Going viral with cancer immunotherapy. Nat. Rev. Cancer 14, 559–567 (2014).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  160. 160.

    Mohn, K. G.-I., Smith, I., Sjursen, H. & Cox, R. J. Immune responses after live attenuated influenza vaccination. Hum. Vaccin. Immunother. 14, 571–578 (2018).

    PubMed  PubMed Central  Article  Google Scholar 

  161. 161.

    Low, N. et al. A randomized, controlled trial of an aerosolized vaccine against measles. N. Engl. J. Med. 372, 1519–1529 (2015).

    PubMed  PubMed Central  Article  Google Scholar 

  162. 162.

    Satti, I. et al. Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trial. Lancet Infect. Dis. 14, 939–946 (2014). Mohn et al. (2018), Low et al. (2015) and Satti et al. provide three successful examples of implementing respiratory mucosal delivery of virus-based vaccines to humans, each against a different type of respiratory mucosal pathogen.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  163. 163.

    Burton, D. R. & Walker, L. M. Rational vaccine design in the time of COVID-19. Cell Host Microbe 27, 695–698 (2020).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  164. 164.

    World Economic Forum. 3 challenges in creating a coronavirus vaccine – and how they are being overcome. World Economic Forum (2020). This commentary identifies the three biggest hurdles to COVID-19 vaccine development and vaccination implementation as developing and selecting the safest and most effective vaccine, acquiring large-scale manufacturing capacities and ensuring transparent and fair vaccine distribution.

  165. 165.

    Bollyky, T. J., Gostin, L. O. & Hamburg, M. A. The equitable distribution of COVID-19 therapeutics and vaccines. JAMA 323, 2462 (2020).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  166. 166.

    Laczkó, D. et al. A single immunization with nucleoside-modified mRNA vaccines elicits strong cellular and humoral immune responses against SARS-CoV-2 in mice. Immunity (2020).

  167. 167.

    McKay, P. F. et al. Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice. Nat. Commun. 11, 3523 (2020).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  168. 168.

    Sánchez-Ramón, S. et al. Trained immunity-based vaccines: a new paradigm for the development of broad-spectrum anti-infectious formulations. Front. Immunol. 9, 2936 (2018).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  169. 169.

    Netea, M. G. et al. Defining trained immunity and its role in health and disease. Nat. Rev. Immunol. 20, 375–388 (2020).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  170. 170.

    de Bree, L. C. J. et al. Non-specific effects of vaccines: current evidence and potential implications. Semin. Immunol. 39, 35–43 (2018).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  171. 171.

    Uthayakumar, D. et al. Non-specific effects of vaccines illustrated through the BCG example: from observations to demonstrations. Front. Immunol. 9, 2869 (2018).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  172. 172.

    Kaufmann, E. et al. BCG educates hematopoietic stem cells to generate protective innate immunity against tuberculosis. Cell 172, 176–190.e19 (2018).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  173. 173.

    Cirovic, B. et al. BCG vaccination in humans elicits trained immunity via the hematopoietic progenitor compartment. Cell Host Microbe (2020).

    Article  PubMed  PubMed Central  Google Scholar 

  174. 174.

    Arts, R. J. W. et al. BCG vaccination protects against experimental viral infection in humans through the induction of cytokines associated with trained immunity. Cell Host Microbe 23, 89–100.e5 (2018).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  175. 175.

    Verrall, A. J. et al. Early clearance of mycobacterium tuberculosis is associated with increased innate immune responses. J. Infect. Dis. 221, 1342–1350 (2019).

    Google Scholar 

  176. 176.

    Moorlag, S. J. C. F. M., Arts, R. J. W., van Crevel, R. & Netea, M. G. Non-specific effects of BCG vaccine on viral infections. Clin. Microbiol. Infect. 25, 1473–1478 (2019).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  177. 177.

    Covián, C., Retamal-Díaz, A., Bueno, S. M., Kalergis, A. M. & Could, B. C. G. Vaccination induce protective trained immunity for SARS-CoV-2? Front. Immunol. 11, 970 (2020).

    PubMed  PubMed Central  Article  Google Scholar 

  178. 178.

    O’Neill, L. A. J. & Netea, M. G. BCG-induced trained immunity: can it offer protection against COVID-19? Nat. Rev. Immunol. 20, 335–337 (2020). This is an overview of the current global effort in clinically testing the potential non-specific protective effect of BCG, a human TB vaccine, on controlling COVID-19 infection and severity, based on the concept of trained innate immunity.

    PubMed  Article  CAS  PubMed Central  Google Scholar 

  179. 179.

    Ordovas-Montanes, J., Beyaz, S., Rakoff-Nahoum, S. & Shalek, A. K. Distribution and storage of inflammatory memory in barrier tissues. Nat. Rev. Immunol. 20, 308–320 (2020).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  180. 180.

    Cardani, A., Boulton, A., Kim, T. S. & Braciale, T. J. Alveolar macrophages prevent lethal influenza pneumonia by inhibiting infection of type-1 alveolar epithelial cells. PLoS Pathog. 13, e1006140 (2017).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  181. 181.

    Guillon, A. et al. Pneumonia recovery reprograms the alveolar macrophage pool. JCI Insight 5, e133042 (2020).

    PubMed Central  Article  Google Scholar 

  182. 182.

    Lakdawala, S. S. & Menachery, V. D. The search for a COVID-19 animal model. Science 368, 942–943 (2020).

    CAS  Article  Google Scholar 

  183. 183.

    Wan, Y., Shang, J., Graham, R., Baric, R. S. & Li, F. Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus. J. Virol. 94, e00127-20 (2020).

    PubMed  PubMed Central  Article  Google Scholar 

  184. 184.

    Rockx, B. et al. Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model. Science 368, 1012–1015 (2020).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  185. 185.

    Munster, V. J. et al. Respiratory disease in rhesus macaques inoculated with SARS-CoV-2. Nature (2020).

    Article  Google Scholar 

  186. 186.

    Shi, J. et al. Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS–coronavirus 2. Science 368, 1016–1020 (2020). Together with Lakdawala and Menachery (2020), Shi et al. provide information on the pros and cons of various animal models of COVID-19 for pathogenesis, immunity and vaccine studies.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  187. 187.

    Zhao, X. et al. Broad and differential animal ACE2 receptor usage by SARS-CoV-2. J. Virol. (2020).

    Article  PubMed  PubMed Central  Google Scholar 

  188. 188.

    Bao, L. et al. The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice. Nature 583, 830–833 (2020).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

Download references


The work was supported by the Canadian Institutes of Health Research (CIHR) COVID-19 Rapid Research Program, the CIHR Foundation Program, the National Sanitarium Association of Canada Innovative Research Program, the Natural Sciences and Engineering Research Council of Canada, the Canadian Foundation for Innovation, Ontario Government, and McMaster University.

Author information




The authors contributed equally to all aspects of the article.

Corresponding authors

Correspondence to Brian D. Lichty or Zhou Xing.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Peer review information

Nature Reviews Immunology thanks P. Klenerman and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Related links

Australian New Zealand Clinical Trials Registry (ANZCTR):

Chinese Clinical Trial Registry (ChiCTR):

EU Clinical Trials Register (EudraCT):

ISRCTN registry:

Pan African Clinical Trials Registry (PACTR):


Acute respiratory distress syndrome

A rapidly developing lung condition characterized by deficient oxygen exchange and shortness of breath, resulting from severe lung injury and inflammation following infection.


Age-related changes in the immune system that lead to a progressive reduction in its ability to develop effective antibody and cellular responses to infections and vaccinations.

Trained immunity

A persisting reset state of the innate immune system long after the initial antigen or microbial exposure that leads to enhanced responsiveness to the same or an unrelated antigen or microorganism.

Fc-mediated effector functions

Immune functions that are mediated through the interaction of the constant Fc region of antibodies with innate immune molecules, complement proteins and specialized Fc receptors expressed by innate immune cells. The resulting functions include complement-dependent cytotoxicity and antibody-dependent cellular phagocytosis or cell-mediated cytotoxicity.

Respiratory mucosal vaccination

Direct administration of a vaccine to the respiratory tract by either intranasal delivery or aerosol inhalation.

Parenteral vaccination

Administration of a vaccine via the skin, muscle or blood vessel.

Antibody-dependent enhancement

(ADE). ADE of disease results when vaccine-induced non-neutralizing or weakly neutralizing antibodies bind to newly infecting virus to promote enhanced virus uptake into host cells via Fcγ receptors. This phenomenon has been observed experimentally or clinically following vaccination against viral pathogens such as dengue virus, respiratory syncytial virus and feline coronavirus.

Macrophage activation syndrome

Also known as cytokine storm or secondary hemophagocytic lymphohistocytosis. A clinical state of systemic hyperinflammation that is characterized by hypercytokinaemia, fever, adenopathy, hepatosplenomegaly, cytopenias and activation of intravascular coagulation.

Virus-like particles

(VLPs). A type of subunit vaccine based on multiple virus-derived proteins that are assembled to mimic the organization and conformation of authentic native viruses but that lack the viral genome.


Biochemical components additional to vaccine antigens that are included in a vaccine formulation to help stimulate an adaptive immune response to vaccine antigens by activating innate immune cells. Often, non-live vaccines such as inactivated virus, protein subunit and nucleic acid vaccines require immune adjuvants.

Homologous or heterologous prime–boost vaccination

A repeated immunization regimen designed to increase and sustain vaccine-induced immune responses. It may involve repeated delivery of the same vaccine (homologous) or sequential delivery of different vaccine platforms (heterologous).

US Operation Warp Speed

A public–private partnership initiated and funded by the US government to accelerate and coordinate the development, manufacture and distribution of coronavirus disease 2019 (COVID-19) vaccines, therapeutics and diagnostics. It was introduced by the Trump administration in early April 2020.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Jeyanathan, M., Afkhami, S., Smaill, F. et al. Immunological considerations for COVID-19 vaccine strategies. Nat Rev Immunol 20, 615–632 (2020).

Download citation


Sign up for the Nature Briefing newsletter for a daily update on COVID-19 science.
Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing